TuHURA Biosciences filed an 8-K on November 3, 2025, detailing significant corporate actions, business developments, and material financial risks, supported by Unaudited Pro Forma Condensed Combined Financial Information reflecting the Kineta (June 2025) and Kintara (Oct 2024) mergers, with TuHURA as the accounting acquirer in both.
Financial Condition and Funding Risks The company reports recurring losses since inception, culminating in an accumulated deficit of $127.3 million as of June 30, 2025. Substantial doubt exists regarding the ability to continue as a going concern, with the cur
...